RecruitingPhase 3NCT06522555

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Intervention
polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide(drug)
Enrollment
100 enrolled
Eligibility
70 years · All sexes
Timeline
20242029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06522555 on ClinicalTrials.gov

Other trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

← Back to all trials